|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MiR-658, paired box gene 3 (PAX3) and met proto-oncogene (MET) are overexpressed in gastric cancer while PAX3 and MET can be regulated by miRNA.
|
29630524 |
2018 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To investigate methods for assessing MET overexpression in gastric cancer, we conducted immunohistochemistry using a new anti-Total MET monoclonal antibody in a single-institution cohort of 495 patients.
|
23807774 |
2013 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that increased levels of co-amplification of MYC and MET correlate with enhanced growth potential in this case of gastric carcinoma.
|
7664243 |
1995 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The findings from present study indicated that higher MET gene amplification and expression in gastric cancer was an indicator of poor prognosis.
|
24416238 |
2014 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overexpression of MET occurs frequently in gastric cancer and has been proposed as a potential predictive biomarker for anti-MET therapy.
|
26690587 |
2016 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, the profile of the gastric cancer samples observed that sf-RON was frequently upregulated in MET-positive gastric cancer.
|
26528757 |
2015 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MET amplification has been clinically credentialed as a therapeutic target in gastric cancer, but the molecular mechanisms underlying sensitivity and resistance to MET inhibitors are still not well understood.
|
28881678 |
2017 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Similar results were obtained in additional GC cell lines with amplification of MET or the FGF receptor FGFR2 MKN45 murine xenograft experiments demonstrated the antitumor activity of M-COPA in vivo Taken together, our results offer an initial preclinical proof of concept for the use of M-COPA as a candidate treatment option for MET-addicted GC, with broader implications for targeting the Golgi apparatus as a novel cancer therapeutic approach.
|
27197184 |
2016 |
|
Stomach Carcinoma
|
0.400 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Stomach Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MET rs40239 may serve as a prognostic biomarker in locoregional gastric cancer.
|
25203738 |
2014 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Candidate tumor suppressor genes at FRA7G are coamplified with MET and do not suppress malignancy in a gastric cancer.
|
12620387 |
2003 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MET is overexpressed in microsatellite instability-high gastric carcinoma.
|
30455128 |
2019 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MACC1, HGF and c-Met might cooperatively participate in the malignant progression of gastric cancer.
|
29435059 |
2018 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, MET overexpression could serve as a prognostic biomarker and a potential therapeutic target for gastric cancer.
|
28052014 |
2017 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, this study suggests that MET mRNA expression assessed by RNA ISH could be useful as a potential marker to identify MET oncogene-addicted GC.
|
25364819 |
2014 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Volumetric parameters on <sup>18</sup>F-FDG PET/CT predict the survival of patients with gastric cancer associated with their expression status of c-MET.
|
31395059 |
2019 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
|
28314274 |
2017 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, we observed an inverse correlation between the expression of miR-144 and MET mRNA in GC metastatic tissues.
|
25927670 |
2015 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study assessed the incidence of MET expression and gene amplification in tumors of Western patients with gastric cancer.
|
21393565 |
2011 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study aimed to explore the molecular segmentation of several known therapeutics targets, human epidermal growth factor receptor 2 (HER2), MET and fibroblast growth factor receptor 2 (FGFR2), within GC using clinically approved or investigational kits and scoring criteria.
|
24518603 |
2014 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The presence of TPR-MET mRNA was determined in gastric tissue from 19 patients with gastric carcinoma and in the gastric mucosa of 18 first-degree relatives without gastric carcinoma and in the gastric mucosa of 18 first-degree relatives without gastric carcinoma using a nested reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern blot analysis.
|
10760755 |
2000 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression of circ-DB and MET in GCa tissues was significantly higher than that in the corresponding adjacent tissues.
|
31799656 |
2019 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
|
30511201 |
2019 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results overall suggest that amplification of the c-met gene might participate in carcinogenesis and progression of stomach cancer, especially scirrhous type stomach carcinoma.
|
1333188 |
1992 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This article reports a case of c-MET gene amplification in advanced gastric cancer with liver metastases.
|
31499745 |
2019 |